MCID: BPL002
MIFTS: 47

Bipolar I Disorder

Categories: Genetic diseases, Mental diseases, Neuronal diseases, Rare diseases

Aliases & Classifications for Bipolar I Disorder

MalaCards integrated aliases for Bipolar I Disorder:

Name: Bipolar I Disorder 12 73 15 17 70

Classifications:



External Ids:

Disease Ontology 12 DOID:14042
ICD9CM 34 296.50
SNOMED-CT 67 49468007
UMLS 70 C0236773 C0853193

Summaries for Bipolar I Disorder

Disease Ontology : 12 A bipolar disorder that is characterized by at least one manic or mixed episode.

MalaCards based summary : Bipolar I Disorder is related to substance abuse and conduct disorder. An important gene associated with Bipolar I Disorder is HTR2A (5-Hydroxytryptamine Receptor 2A), and among its related pathways/superpathways are G-Beta Gamma Signaling and Circadian entrainment. The drugs Coal tar and Oxcarbazepine have been mentioned in the context of this disorder. Affiliated tissues include brain, cortex and amygdala, and related phenotypes are behavior/neurological and integument

Wikipedia : 73 Bipolar I disorder (BD-I; pronounced "type one bipolar disorder") is a type of bipolar spectrum disorder... more...

Related Diseases for Bipolar I Disorder

Diseases in the Bipolar Disorder family:

Bipolar Ll Disorder Bipolar I Disorder

Diseases related to Bipolar I Disorder via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 216)
# Related Disease Score Top Affiliating Genes
1 substance abuse 30.6 SLC6A4 HTR2A HTR1A DRD2 COMT BDNF
2 conduct disorder 30.6 SLC6A4 DRD2 COMT
3 depression 30.5 TPH2 SLC6A4 HTR2C HTR2A HTR1A BDNF
4 headache 30.5 SLC6A4 COMT CACNA1C
5 tardive dyskinesia 30.4 HTR2A DRD2 COMT
6 drug dependence 30.3 SLC6A4 DRD2 DRD1 BDNF
7 acute stress disorder 30.3 SLC6A4 HTR1A BDNF
8 early-onset schizophrenia 30.3 DRD2 DRD1 BDNF
9 substance dependence 30.3 SLC6A4 DTNBP1 DRD2 COMT BDNF
10 obsessive-compulsive personality disorder 30.2 SLC6A4 HTR2A COMT
11 neuroleptic malignant syndrome 30.2 HTR2A HTR1A DRD2
12 social phobia 30.2 SLC6A4 HTR2A HTR1A DRD2 COMT BDNF
13 endogenous depression 30.1 TPH2 SLC6A4 HTR2A HTR1A DRD2 COMT
14 agnosia 30.1 HTR1A COMT BDNF
15 hyperprolactinemia 30.1 HTR2C HTR2A DRD2
16 cyclothymic disorder 30.1 SLC6A4 HTR2C HTR2A DRD2 COMT
17 tobacco addiction 30.0 SLC6A4 HTR2A DRD2 DRD1 COMT BDNF
18 melancholia 29.9 SLC6A4 HTR2A HTR1A BDNF
19 agoraphobia 29.9 SLC6A4 HTR2A HTR1A COMT
20 mood disorder 29.9 TPH2 SLC6A4 PER3 HTR2C HTR2A HTR1A
21 alcohol use disorder 29.8 SLC6A4 HTR2C HTR2A HTR1A DRD2 DRD1
22 generalized anxiety disorder 29.8 SLC6A4 HTR2A HTR1A DRD2 COMT BDNF
23 sleep apnea 29.8 SLC6A4 HTR2C HTR2A BDNF
24 anxiety 29.8 TPH2 SLC6A4 HTR2C HTR2A HTR1A DRD2
25 mental depression 29.8 TPH2 SLC6A4 HTR2C HTR2A HTR1A DRD2
26 sexual disorder 29.8 SLC6A4 HTR2C HTR2A HTR1A BDNF
27 schizoaffective disorder 29.7 TIMELESS SLC6A4 PER3 HTR2A HTR1A DTNBP1
28 post-traumatic stress disorder 29.7 SLC6A4 NRG1 HTR2A DRD2 COMT BDNF
29 dystonia 29.7 HTR2A DRD2 DRD1 COMT BDNF
30 alcohol dependence 29.7 TPH2 SLC6A4 HTR2C HTR2A HTR1A DRD2
31 personality disorder 29.7 TPH2 SLC6A4 HTR2C HTR2A HTR1A DRD2
32 dysthymic disorder 29.7 SLC6A4 HTR2C HTR2A HTR1A COMT BDNF
33 panic disorder 29.6 TPH2 SLC6A4 HTR2C HTR2A HTR1A DRD2
34 cocaine dependence 29.6 TPH2 SLC6A4 HTR2A DRD2 DRD1 COMT
35 intermittent explosive disorder 29.6 SLC6A4 HTR2C HTR2A HTR1A COMT
36 obsessive-compulsive disorder 29.5 TPH2 SLC6A4 HTR2C HTR2A HTR1A DRD2
37 borderline personality disorder 29.3 TPH2 SLC6A4 HTR2C HTR2A HTR1A DRD2
38 impulse control disorder 29.2 SLC6A4 HTR2C HTR2A HTR1A DRD2 DRD1
39 attention deficit-hyperactivity disorder 29.2 ZNF804A TPH2 SLC6A4 HTR2C HTR2A HTR1A
40 body mass index quantitative trait locus 11 29.2 HTR2C HTR2A HTR1A DRD2 COMT BDNF
41 schizotypal personality disorder 29.0 ZNF804A NRG1 HTR2A DTNBP1 DAO COMT
42 bipolar disorder 28.8 ZNF804A TPH2 TIMELESS SLC6A4 PER3 NRG1
43 sleep disorder 28.6 SLC6A4 PER3 HTR2C HTR2A HTR1A COMT
44 major depressive disorder 28.4 ZNF804A TPH2 SLC6A4 PER3 HTR2C HTR2A
45 schizophreniform disorder 28.3 ZNF804A NRG1 HTR2C HTR2A DTNBP1 DRD2
46 schizophrenia 27.9 ZNF804A TPH2 SLC6A4 NRG1 HTR2C HTR2A
47 alzheimer disease 27.9 SLC6A4 NRG1 HTR2C HTR2A DRD2 DRD1
48 autism spectrum disorder 27.8 ZNF804A TPH2 SLC6A4 NRG1 HTR2C HTR2A
49 psychotic disorder 27.7 ZNF804A TPH2 SLC6A4 NRG1 HTR2C HTR2A
50 autism 27.1 ZNF804A TPH2 SLC6A4 NRG1 HTR2C HTR2A

Graphical network of the top 20 diseases related to Bipolar I Disorder:



Diseases related to Bipolar I Disorder

Symptoms & Phenotypes for Bipolar I Disorder

MGI Mouse Phenotypes related to Bipolar I Disorder:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.25 ANK3 ARNTL BDNF CACNA1C COMT DAO
2 integument MP:0010771 9.96 ARNTL BDNF CACNA1C DRD1 DRD2 DTNBP1
3 nervous system MP:0003631 9.83 ANK3 ARNTL BDNF CACNA1C COMT DAO
4 muscle MP:0005369 9.76 ARNTL CACNA1C DRD1 DRD2 DTNBP1 HTR2A
5 respiratory system MP:0005388 9.17 ANK3 ARNTL BDNF COMT DRD1 DRD2

Drugs & Therapeutics for Bipolar I Disorder

Drugs for Bipolar I Disorder (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 90)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Coal tar Approved Phase 4 8007-45-2
2
Oxcarbazepine Approved Phase 4 28721-07-5 34312
3
Sibutramine Approved, Illicit, Investigational, Withdrawn Phase 4 106650-56-0 5210
4
Cocaine Approved, Illicit Phase 4 50-36-2 446220 5760
5
Fluoxetine Approved, Vet_approved Phase 4 54910-89-3 3386
6
Carbamazepine Approved, Investigational Phase 4 298-46-4 2554
7
Choline Approved, Nutraceutical Phase 4 62-49-7 305
8
Lecithin Experimental Phase 4 8002-43-5
9 Neurotransmitter Agents Phase 4
10 Antidepressive Agents Phase 4
11 Gastrointestinal Agents Phase 4
12 Antiemetics Phase 4
13 Serotonin Uptake Inhibitors Phase 4
14 Cytochrome P-450 Enzyme Inhibitors Phase 4
15 Anti-Obesity Agents Phase 4
16 Appetite Depressants Phase 4
17 Cytidine Diphosphate Choline Phase 4
18 Antimetabolites Phase 4
19 Nootropic Agents Phase 4
20 Lipid Regulating Agents Phase 4
21 Hypolipidemic Agents Phase 4
22 Analgesics, Non-Narcotic Phase 4
23 Analgesics Phase 4
24
Serotonin Investigational, Nutraceutical Phase 4 50-67-9 5202
25
Citalopram Approved Phase 3 59729-33-8 2771
26
Bupropion Approved Phase 3 34841-39-9, 34911-55-2 444
27
Ethanol Approved Phase 3 64-17-5 702
28
Clozapine Approved Phase 3 5786-21-0 2818
29
Asenapine Approved Phase 3 85650-56-2, 65576-45-6 3001386
30
Lamotrigine Approved, Investigational Phase 3 84057-84-1 3878
31
Brexpiprazole Approved, Investigational Phase 3 913611-97-9 11978813
32
Topiramate Approved Phase 3 97240-79-4 5284627
33
Haloperidol Approved Phase 3 52-86-8 3559
34
Promethazine Approved, Investigational Phase 3 60-87-7 4927
35
Histamine Approved, Investigational Phase 3 51-45-6, 75614-87-8 774
36
Norepinephrine Approved Phase 3 51-41-2 439260
37
Diphenhydramine Approved, Investigational Phase 3 58-73-1, 147-24-0 3100
38
Lorazepam Approved Phase 3 846-49-1 3958
39
Iloperidone Approved Phase 3 133454-47-4 71360
40
Olanzapine Approved, Investigational Phase 3 132539-06-1 4585 135398745
41
Cariprazine Approved, Investigational Phase 3 839712-12-8 11154555
42
tannic acid Approved Phase 3 1401-55-4
43
Benzocaine Approved, Investigational Phase 3 1994-09-7, 94-09-7 2337
44
Modafinil Approved, Investigational Phase 3 68693-11-8 4236
45
Dexetimide Withdrawn Phase 3 21888-98-2
46 Dopamine Uptake Inhibitors Phase 3
47 Anticonvulsants Phase 3
48 Sodium Channel Blockers Phase 3
49 Diuretics, Potassium Sparing Phase 3
50 calcium channel blockers Phase 3

Interventional clinical trials:

(show top 50) (show all 155)
# Name Status NCT ID Phase Drugs
1 Neurofunctional and Neurochemical Markers of Treatment Response in Bipolar Disorder Unknown status NCT00608075 Phase 4 lithium;Lithium
2 ARIQUELI: Potentiation of Quetiapine Treatment in Bipolar 1 Nonresponders Patients With Lithium or Aripiprazole Unknown status NCT01710163 Phase 4 Lithium;Aripiprazole
3 Comparative Efficacy and Acceptability of Lithium, Valproate, Oxcarbazepine, Quetiapine, Olanzapine, and Ziprasidone in Bipolar I Disorder, Manic or Mixed Phase Unknown status NCT01893229 Phase 4 Lithium;Valproate;Oxcarbazepine;Quetiapine;Olanzapine;Ziprasidone
4 A Double-Blind Placebo Controlled Trial of Divalproex and Olanzapine in Bipolar I Disorder, Mixed Episode Completed NCT00402324 Phase 4 olanzapine;placebo;divalproex
5 Efficacy and Tolerability of the Combination of LIthium and CArbamazepine Compared to Lithium and VALproic Acid in the Treatment of Young Bipolar Patients Completed NCT00976794 Phase 4 lithium plus carbamazepine;lithium plus valproate
6 A Long-Term, Open-Label, Safety Study of Oral Olanzapine in Adolescents With Bipolar I Disorder (Manic or Mixed Episodes) or Schizophrenia Completed NCT00982020 Phase 4 Olanzapine
7 A Phase IV, Multi-Center, Open-Label, Safety and Effectiveness Study of Extended-Release Carbamazepine in the Treatment of Mania in Children and Adolescents Aged 10-17 Years With Acute Manic or Mixed Bipolar I Disorder. Completed NCT00350857 Phase 4 Extended-Release Carbamazepine
8 Treatment of Primary Mood Disorders in the Comorbidly Ill Completed NCT00178061 Phase 4
9 Sequential Multiple Assignment Randomized Treatment (SMART) for Bipolar Disorder Completed NCT01588457 Phase 4 Lithium;Divalproex;Lamotrigine;Quetiapine
10 A 52-week, Open-label Extension Study to Evaluate the Safety and Tolerability of Licarbazepine in the Treatment of Manic Episodes of Bipolar I Disorder Completed NCT00139594 Phase 4 licarbazepine
11 Olanzapine Versus Placebo in the Treatment of Mania in Adolescents With Bipolar I Disorder Completed NCT00050206 Phase 4 Olanzapine;Placebo
12 The Assessment of a Anti-Obesity Agent for the Treatment of Olanzapine-Associated Weight Gain in Patients With Schizophrenia, Schizophreniform Disorder, Schizoaffective Disorder and Bipolar I Disorder Completed NCT00044187 Phase 4 Sibutramine
13 Olanzapine Versus Active Comparator in the Treatment of Bipolar I Disorder, Manic or Mixed Completed NCT00034580 Phase 4 olanzapine;risperidone
14 A Multicenter, Double-blind, Study of the Efficacy and Safety of Aripiprazole in Combination With Lamotrigine in the Long-term Maintenance Treatment of Patients With Bipolar I Disorder With a Recent Manic or Mixed Episode Completed NCT00277212 Phase 4 Lamotrigine + Aripiprazole;Lamotrigine + Placebo
15 Olanzapine Versus Divalproex and Placebo in the Treatment of Mild to Moderate Mania Associated With Bipolar I Disorder Completed NCT00094549 Phase 4 olanzapine;divalproex sodium;placebo
16 Efficacy of Aripiprazole in Combination With Lithium or Valproate in the Long-Term Maintenance Treatment of Bipolar I Disorder in Outpatients Partially Nonresponsive to Lithium or Valproate Monotherapy Completed NCT00261443 Phase 4 Lithium or Valproate with placebo (PBO);Lithium or Valproate with Aripiprazole
17 Olanzapine Plus Carbamazepine Versus Carbamazepine Alone in the Treatment of Manic or Mixed Episodes Associated With Bipolar I Disorder Completed NCT00190892 Phase 4 olanzapine;carbamazepine
18 A 12-week, Randomized, Double-blind, Parallel-group, Placebo-controlled Trial of Citicoline as an add-on Therapy Will be Conducted in 200 Outpatients With Bipolar I Disorder and Cocaine Dependence. Completed NCT00619723 Phase 4 Citicoline;Placebo
19 Study to Assess the Efficacy and Safety of Olanzapine and Fluoxetine Combination Versus Placebo in Patients Ages 10-17 in the Treatment of Major Depressive Episodes Associated With Bipolar I Disorder Completed NCT00844857 Phase 4 Olanzapine Fluoxetine Combination (OFC);Placebo
20 A Double Blind Study To Evaluate the Dose Tolerance and Safety of Equetro (Carbamazepine) Versus Placebo Followed by a Long-Term Maintenance in Children and Adolescents Aged 10-17 Years With Acute Manic or Mixed Bipolar I Disorder Recruiting NCT02623504 Phase 4 Carbamazepine;Placebo
21 A Multicenter, 52-week, Provider- Randomized, Pragmatic Trial to Assess the Differences in ABILIFY MYCITE - a Digital Medicine System (DMS) Versus Treatment as Usual (TAU) for Adults With Schizophrenia, Bipolar I Disorder, or Major Depression Currently Using Aripiprazole Active, not recruiting NCT03881449 Phase 4
22 A Randomized, Double-blind, Placebo Controlled Study of the Efficacy of Adjunctive Lithium for the Treatment of Psychotic Mania Followed by an Open Label Long-term Safety Period. Withdrawn NCT01495156 Phase 4 Lithium treatment in combination with a SGA (Second Generation Antipsychotic);Placebo/Adjunctive SGA treatment
23 Mood Stabilizer Plus Antidepressant Versus Mood Stabilizer Plus Placebo in the Maintenance Treatment of Bipolar Disorder Unknown status NCT00958633 Phase 3 Escitalopram;Wellbutrin XL
24 Double-Blind, Randomized, Placebo-Controlled, Parallel-Group, Multicenter, Efficacy and Safety Study of Lithium in Bipolar I Disorder Unknown status NCT00422331 Phase 3 Lithium Carbonate Capsule
25 An Open-Label Long-Term Study to Evaluate the Safety of Depakote Extended Release Tablets in the Treatment of Mania Associated With Bipolar Disorder in Children and Adolescents Completed NCT00195767 Phase 3 divalproex sodium
26 A Multicenter, Randomized, Placebo-Controlled, Parallel-Group, Double-Blind, Phase III Study to Compare the Efficacy and Safety of Quetiapine Fumarate (SEROQUEL®) Versus Placebo as Adjunct Therapy With Mood Stabilizers (Lithium or Divalproex) for the Treatment of Alcohol Dependence in Patients With Bipolar I Disorder Completed NCT00114686 Phase 3 Quetiapine fumarate;lithium;divalproex
27 A 52-week, Open Label Extension Study to Evaluate the Safety and Tolerability of Licarbazepine 750 - 2000 mg/d in the Treatment of Manic Episodes of Bipolar I Disorder. Completed NCT00238485 Phase 3 Licarbazepine
28 A Multicenter, Randomized, Parallel-Group, Double-Blind, Phase 3 Comparison of the Efficacy & Safety of Quetiapine Fumarate to Placebo When Used as Adjunct to Mood Stabilizers (Lithium or Valproate) in the Maintenance Treatment of Bipolar I Disorder in Adult Patients (Abbreviated) Completed NCT00107731 Phase 3 quetiapine fumarate;lithium;divalproex
29 A Long-term Open-label Study of the Safety and Tolerability of Cariprazine in Patients With Bipolar I Disorder Completed NCT01059539 Phase 3 Cariprazine
30 A Double-Blind Randomized Placebo Controlled Study of Quetiapine for the Treatment of Depression in Adolescents With Bipolar Disorder Completed NCT00232414 Phase 3 Quetiapine
31 A Random Assignment,Parallel Group, Open Label Comparison of Clinical Outcomes and Resource Utilization Among Bipolar Disorder Patients Receiving Either Long Acting Injectable Risperidone Microspheres (Risperdal Consta® ) or Other Second Generation Oral Antipsychotic Agents: A 15 Month Study Completed NCT00177164 Phase 3 Injectable Risperidone (Consta) or oral antipsychotic
32 A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of Aripiprazole in the Treatment of Patients With Bipolar I Disorder With a Major Depressive Episode. CN138-146 LT is the 26-week Open Label Extension Phase of the Above Titled Protocol, CN138-146 ST. Completed NCT00094432 Phase 3 Aripiprazole;Placebo
33 Study of Aripiprazole in the Treatment of Patients With Acute Symptoms of Bipolar Disorder Completed NCT00046384 Phase 3 aripiprazole
34 Efficacy and Safety of Olanzapine in the Extended Treatment for Manic or Mixed Episode of Bipolar I Disorder Completed NCT00266630 Phase 3 olanzapine;lithium;valproate;carbamazepine
35 A 52-week, Open-label Extension Study to Evaluate the Safety and Tolerability of Licarbazepine 750- 2000 mg/Day in the Treatment of Manic Episodes of Bipolar I Disorder Completed NCT00228059 Phase 3 Licarbazepine
36 An Open-Label Study to Evaluate the Safety of Depakote ER in the Treatment of Mania Associated With Bipolar I Disorder in Children and Adolescents Completed NCT00195780 Phase 3 Divalproex Sodium (Depakote ER)
37 Safety and Efficacy of Olanzapine (LY170053) in the Long-term Treatment for Patients With Bipolar I Disorder, Depressed Completed NCT00618748 Phase 3 Olanzapine
38 A Multicenter, Investigative Study of the Safety and Efficacy of Extended Administration of Aripiprazole in Combination With Mood Stabilizer for the Treatment of Patients With Bipolar Disorder Experiencing a Manic or Mixed Episode Completed NCT00606320 Phase 3 Aripiprazole
39 A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group-Comparison Trial of Aripiprazole in the Treatment of Patients With Bipolar Disorder Experiencing a Manic or Mixed Episode Completed NCT00606281 Phase 3 Aripiprazole;placebo
40 A Multicenter Investigative Study of the Safety and Efficacy of Long-term Administration of Aripiprazole in Combination With Mood Stabilizer for the Treatment of Patients With Bipolar Disorder Experiencing a Manic or Mixed Episode Completed NCT00606229 Phase 3 Aripiprazole
41 A Multicenter, Placebo-controlled, Double-blind Investigative Extension Trial of the Safety and Efficacy of Aripiprazole in the Treatment of Patients With Bipolar Disorder Experiencing a Manic or Mixed Episode Completed NCT00606177 Phase 3 Aripiprazole;placebo
42 52-week, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of an Intramuscular Depot Formulation of Aripiprazole (OPC-14597) as Maintenance Treatment in Patients With Bipolar I Disorder Completed NCT01567527 Phase 3 Intramuscular (IM) Depot Aripiprazole;Intramuscular (IM) Depot Placebo
43 A Multicenter, Randomized, Double-blind Trial of Brexpiprazole Versus Placebo for the Acute Treatment Manic Episodes, With or Without Mixed Features, Associated With Bipolar I Disorder Completed NCT03257865 Phase 3 Brexpiprazole;Placebo
44 A Long-Term Study of SM-13496 in Patients With Bipolar I Disorder. Completed NCT01986114 Phase 3 SM-13496
45 Sensoril® (Ashwagandha) - A Standardized Extract From a Medicinal Plant - (Withania Somnifera) for Cognitive Enhancement in Persons With Bipolar Disorder: A Parallel Group, Randomized Double Blind, and Placebo Controlled Study Completed NCT00761761 Phase 3 Sensoril
46 A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Multi-Dose Efficacy and Safety Study of Staccato® Loxapine for Inhalation in Patients With Bipolar I Disorder and Acute Agitation Completed NCT00721955 Phase 3 Inhaled Placebo;Inhaled loxapine 5 mg;Inhaled loxapine 10 mg
47 A Multi-center, Open Label, Flexible Dose, Extension Study of Lurasidone Adjunctive to Lithium or Divalproex in Subjects With Bipolar I Disorder Completed NCT01575561 Phase 3 Lurasidone
48 A Multicenter, Open-label Trial to Evaluate the Safety and Tolerability of Brexpiprazole in the Treatment of Subjects With Bipolar I Disorder Completed NCT03287869 Phase 3 Brexpiprazole
49 Changes in Cognitive Functioning in Euthymic Bipolar Patients Treated With Lurasidone Versus Treatment as Usual; A Randomized, Open-Label Study. Completed NCT02147379 Phase 3 Lurasidone
50 A Multicenter, Double-Blind, Fixed-Dose, Long-Term Extension Trial of the Safety of Asenapine in Subjects Diagnosed With Bipolar 1 Disorder Who Completed Protocol P05691 (Formerly 041044) (Phase3B, Protocol P05692 [Formerly 041045]) Completed NCT01395992 Phase 3 asenapine;asenapine

Search NIH Clinical Center for Bipolar I Disorder

Genetic Tests for Bipolar I Disorder

Anatomical Context for Bipolar I Disorder

MalaCards organs/tissues related to Bipolar I Disorder:

40
Brain, Cortex, Amygdala, Prefrontal Cortex, Eye, Cingulate Cortex, B Lymphoblasts

Publications for Bipolar I Disorder

Articles related to Bipolar I Disorder:

(show top 50) (show all 2271)
# Title Authors PMID Year
1
N-acetylcysteine for depression and glutamate changes in the left prefrontal cortex in adolescents and young adults at risk for bipolar disorder: A pilot study. 61
33797205 2021
2
Association between genetic variants of the norepinephrine transporter gene (SLC6A2) and bipolar I disorder. 61
33340618 2021
3
Two randomized, double-blind, placebo-controlled trials and one open-label, long-term trial of brexpiprazole for the acute treatment of bipolar mania. 61
33691517 2021
4
Systemic inflammation and grey matter volume in schizophrenia and bipolar disorder: Moderation by childhood trauma severity. 61
32540496 2021
5
Hospitalization risk among adults with bipolar I disorder treated with lurasidone versus other oral atypical antipsychotics: a retrospective analysis of Medicaid claims data. 61
33682547 2021
6
Relation of medication adherence to cognitive functions in egyptian patients with bipolar I disorder. 61
33724253 2021
7
A network structure of manic symptoms. 61
33452874 2021
8
Long-acting injectable antipsychotics: what, when, and how. 61
33715640 2021
9
fNIRS study of prefrontal activation during emotion recognition-A Potential endophenotype for bipolar I disorder? 61
33601730 2021
10
Extra-synaptic modulation of GABAA and efficacy in bipolar disorder. 61
33515862 2021
11
Reduced white matter microstructure in bipolar disorder with and without psychosis. 61
33550654 2021
12
A very rare case of priapism under aripiprazole in a patient followed for bipolar disorder: A CARE-compliant report. 61
33537133 2021
13
Bipolar I disorder: a qualitative study of the viewpoints of the family members of patients on the nature of the disorder and pharmacological treatment non-adherence. 61
33557797 2021
14
Impact of duration of untreated illness in bipolar I disorder (manic episodes) on clinical outcome, socioecnomic burden in Egyptian population. 61
33360586 2021
15
Bipolar Disorders: Evaluation and Treatment. 61
33587568 2021
16
Effects of a conventional mood stabilizer alone or in combination with second-generation antipsychotics on recurrence rate and discontinuation rate in bipolar I disorder in the maintenance phase: A systematic review and meta-analysis of randomized, placebo-controlled trials. 61
33561884 2021
17
Cognitive subgroups in first episode bipolar I disorder: Relation to clinical and brain volumetric variables. 61
33089491 2021
18
Melatonin Receptor Gene Polymorphism in Bipolar-I Disorder. 61
33546869 2021
19
Real-World Patterns of Utilization and Costs Associated with Second-Generation Oral Antipsychotic Medication for the Treatment of Bipolar Disorder: A Literature Review. 61
33623386 2021
20
[Lamotrigine in bipolar disorder: preventing depression to treat the disease]. 61
33560270 2021
21
The Rapid Mood Screener (RMS): a novel and pragmatic screener for bipolar I disorder. 61
33300813 2021
22
A pilot investigation of emotional regulation difficulties and mindfulness-based strategies in manic and remitted bipolar I disorder and major depressive disorder. 61
33392824 2021
23
Does guideline-concordant care predict naturalistic outcomes in youth with early stage bipolar I disorder? 61
32949870 2021
24
Impairment in Emotional Intelligence May Be Mood-Dependent in Bipolar I and Bipolar II Disorders. 61
33679472 2021
25
Bilateral pedal edema associated with lurasidone: a case report. 61
33230023 2021
26
Electroconvulsive therapy use in the adult U.S. correctional setting: A case report and literature review. 61
33394509 2021
27
Population Pharmacokinetics of Cariprazine and its Major Metabolites. 61
33141308 2021
28
Functional connectome differences in individuals with hallucinations across the psychosis continuum. 61
33441965 2021
29
Bipolar disorders. 61
33278937 2020
30
Identification of common neural substrates with connectomic abnormalities in four major psychiatric disorders: A connectome-wide association study. 61
33267917 2020
31
Identifying Plasma Biomarkers with high specificity for major depressive disorder: A multi-level proteomics study. 61
32905914 2020
32
Effects of Olanzapine Combined With Samidorphan on Weight Gain in Schizophrenia: A 24-Week Phase 3 Study. 61
32791894 2020
33
Neurocognitive Impairments (NCI) in bipolar disorder: Comparison with schizophrenia and healthy controls. 61
32829193 2020
34
High Correspondence Between Child Behavior Checklist Rule Breaking Behavior Scale with Conduct Disorder in Males and Females. 61
32172405 2020
35
Application of Physiologically Based Pharmacokinetic Modeling to Predict the Effect of Renal Impairment on the Pharmacokinetics of Olanzapine and Samidorphan Given in Combination. 61
33313995 2020
36
Reevaluating the concept of lifelong mood stabilizers in a bipolar I disorder patient: A 25 year case study. 61
33271705 2020
37
Impact of initiating long-acting injectable paliperidone palmitate on relapse and hospitalization in patients with bipolar I disorder: A mirror image retrospective study. 61
33271736 2020
38
Ovarian Stimulation for Infertility in a Woman With Bipolar I Disorder. 61
33271644 2020
39
Altered brain creatine cycle metabolites in bipolar I disorder with childhood abuse: A 1H magnetic resonance spectroscopy study. 61
33387596 2020
40
Aripiprazole monotherapy as transdiagnostic intervention for the treatment of mental disorders: An umbrella review according to TRANSD criteria. 61
33077324 2020
41
Association of pro-inflammatory cytokines with clinical features in euthymic patients with Bipolar-I-Disorder. 61
32871531 2020
42
Endoxifen: A new, protein kinase C inhibitor to treat acute and mixed mania associated with bipolar I disorder. 61
33368969 2020
43
Genetic impact of ZNF804A on cognitive function in patients with bipolar I disorder. 61
32941385 2020
44
Comorbidity and patterns of familial aggregation in attention-deficit/hyperactivity disorder and bipolar disorder in a family study of affective and anxiety spectrum disorders. 61
32882577 2020
45
The association between carotid atherosclerosis and treatment with lithium and antipsychotics in patients with bipolar disorder. 61
32900219 2020
46
COVID-19 Transmission in a Psychiatric Long-Term Care Rehabilitation Facility: An Observational Study. 61
33166098 2020
47
Role of autobiographical memory in the impact of MBCT on dysfunctional attitudes, depressive symptoms and anxiety in bipolar I patients. 61
32739709 2020
48
Patterns and clinical correlates of lifetime alcohol consumption in women and men with bipolar disorder: Findings from the UK Bipolar Disorder Research Network. 61
32239612 2020
49
Gender and mental health service use in bipolar disorder: national cohort study. 61
33153508 2020
50
Differences in mitochondrial DNA copy number between patients with bipolar I and II disorders. 61
33190840 2020

Variations for Bipolar I Disorder

Expression for Bipolar I Disorder

Search GEO for disease gene expression data for Bipolar I Disorder.

Pathways for Bipolar I Disorder

Pathways related to Bipolar I Disorder according to GeneCards Suite gene sharing:

(show all 17)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.86 HTR2C HTR2A DRD2 DRD1 CACNA1C BDNF
2
Show member pathways
12.63 PER3 DRD2 DRD1 COMT CACNA1C ARNTL
3 12.42 TPH2 KCTD12 HTR1A DTNBP1 COMT ARNTL
4 12.21 HTR2C HTR2A DRD1 CACNA1C
5 12.17 HTR1A DRD2 DRD1 CACNA1C BDNF
7 11.98 TPH2 SLC6A4 HTR2A HTR1A BDNF
8
Show member pathways
11.87 DRD2 DRD1 CACNA1C BDNF
9 11.79 TPH2 SLC6A4 HTR2C HTR2A HTR1A CACNA1C
10
Show member pathways
11.76 DRD2 DRD1 CACNA1C
11
Show member pathways
11.76 HTR2C HTR2A HTR1A DRD2 DRD1
12 11.7 HTR2C HTR2A DRD2 DRD1
13 10.87 HTR2C HTR2A
14 10.86 HTR2C DRD2
15 10.8 TPH2 SLC6A4 HTR2C HTR2A HTR1A
16 10.68 TIMELESS ARNTL
17
Show member pathways
10.46 TPH2 SLC6A4 HTR1A DRD2 DRD1 COMT

GO Terms for Bipolar I Disorder

Cellular components related to Bipolar I Disorder according to GeneCards Suite gene sharing:

(show all 12)
# Name GO ID Score Top Affiliating Genes
1 plasma membrane GO:0005886 10.31 ZNF804A SLC6A4 NRG1 KCTD12 HTR2C HTR2A
2 integral component of plasma membrane GO:0005887 10.03 SLC6A4 NRG1 HTR2C HTR2A HTR1A DRD2
3 cell junction GO:0030054 9.91 SLC6A4 KCTD12 HTR2A DTNBP1 DRD1 CACNA1C
4 axon GO:0030424 9.76 ZNF804A NRG1 HTR2A DTNBP1 DRD2 COMT
5 postsynaptic membrane GO:0045211 9.72 KCTD12 DTNBP1 COMT CACNA1C ANK3
6 sarcolemma GO:0042383 9.69 DTNBP1 CACNA1C ANK3
7 integral component of presynaptic membrane GO:0099056 9.65 SLC6A4 HTR2A DRD2
8 dendritic spine GO:0043197 9.65 ZNF804A DTNBP1 DRD2 DRD1 COMT
9 integral component of postsynaptic membrane GO:0099055 9.63 SLC6A4 HTR2A DRD2
10 dendrite GO:0030425 9.61 HTR2C HTR2A HTR1A DRD2 DRD1 COMT
11 G protein-coupled serotonin receptor complex GO:0098666 9.4 HTR2C HTR2A
12 synapse GO:0045202 9.36 SLC6A4 NRG1 KCTD12 HTR2C HTR2A HTR1A

Biological processes related to Bipolar I Disorder according to GeneCards Suite gene sharing:

(show all 32)
# Name GO ID Score Top Affiliating Genes
1 signal transduction GO:0007165 10.24 NRG1 HTR2C HTR2A HTR1A DRD2 DRD1
2 positive regulation of gene expression GO:0010628 9.91 ZNF804A SLC6A4 NRG1 DTNBP1 DRD1 ANK3
3 cellular calcium ion homeostasis GO:0006874 9.81 HTR2C HTR2A DRD2
4 locomotory behavior GO:0007626 9.79 NRG1 HTR2C DRD2
5 memory GO:0007613 9.78 SLC6A4 HTR2A BDNF
6 circadian regulation of gene expression GO:0032922 9.77 PER3 DRD2 ARNTL
7 regulation of synaptic vesicle exocytosis GO:2000300 9.71 HTR2A DTNBP1 DRD2
8 release of sequestered calcium ion into cytosol GO:0051209 9.7 HTR2C HTR2A DRD2
9 circadian rhythm GO:0007623 9.67 TPH2 TIMELESS SLC6A4 ARNTL
10 dopamine receptor signaling pathway GO:0007212 9.65 DRD2 DRD1
11 temperature homeostasis GO:0001659 9.65 HTR2A DRD2
12 adenylate cyclase-activating adrenergic receptor signaling pathway GO:0071880 9.65 DRD2 DRD1
13 positive regulation of cytosolic calcium ion concentration involved in phospholipase C-activating G protein-coupled signaling pathway GO:0051482 9.65 HTR2C DRD2 DRD1
14 vasoconstriction GO:0042310 9.64 SLC6A4 HTR1A
15 behavioral response to cocaine GO:0048148 9.63 HTR2A DRD2
16 G protein-coupled serotonin receptor signaling pathway GO:0098664 9.63 HTR2C HTR2A HTR1A
17 prepulse inhibition GO:0060134 9.62 DRD2 DRD1
18 synaptic transmission, dopaminergic GO:0001963 9.62 DRD2 DRD1
19 negative regulation of synaptic transmission, glutamatergic GO:0051967 9.6 HTR2A DRD2
20 phospholipase C-activating dopamine receptor signaling pathway GO:0060158 9.58 DRD2 DRD1
21 serotonin receptor signaling pathway GO:0007210 9.58 HTR2A HTR1A
22 regulation of dopamine secretion GO:0014059 9.58 HTR2A DTNBP1 DRD2
23 regulation of potassium ion transport GO:0043266 9.57 DRD2 ANK3
24 cerebral cortex GABAergic interneuron migration GO:0021853 9.56 DRD2 DRD1
25 regulation of dopamine uptake involved in synaptic transmission GO:0051584 9.55 DRD2 DRD1
26 positive regulation of phosphatidylinositol biosynthetic process GO:0010513 9.51 HTR2C HTR2A
27 dopamine metabolic process GO:0042417 9.5 DRD2 DRD1 COMT
28 phospholipase C-activating serotonin receptor signaling pathway GO:0007208 9.49 HTR2C HTR2A
29 G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger GO:0007187 9.46 HTR2C HTR2A HTR1A DRD1
30 behavior GO:0007610 9.43 HTR2C HTR2A HTR1A
31 synapse assembly GO:0007416 9.26 NRG1 DRD2 DRD1 BDNF
32 response to drug GO:0042493 9.1 SLC6A4 HTR2C HTR2A DRD2 DRD1 COMT

Molecular functions related to Bipolar I Disorder according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 neurotransmitter receptor activity GO:0030594 9.58 HTR2C HTR2A HTR1A
2 dopamine binding GO:0035240 9.37 DRD2 DRD1
3 G protein-coupled serotonin receptor activity GO:0004993 9.33 HTR2C HTR2A HTR1A
4 dopamine neurotransmitter receptor activity GO:0004952 9.32 DRD2 DRD1
5 Gq/11-coupled serotonin receptor activity GO:0001587 9.26 HTR2C HTR2A
6 1-(4-iodo-2,5-dimethoxyphenyl)propan-2-amine binding GO:0071886 8.96 HTR2C HTR2A
7 serotonin binding GO:0051378 8.92 SLC6A4 HTR2C HTR2A HTR1A

Sources for Bipolar I Disorder

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Apr-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
Content
Loading form....